SCHEMBL18677293

SCHEMBL18677293

COCCOCCNC1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 5/20 0.47
FOXM1 Q08050 2/20 0.46
ALDH1A1 P00352 3/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
LMNA P02545 1/20 0.42
EPHX2 P34913 1/20 0.42
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21842124 0.90 SMN1; SMN2 (0.54) SMN1; SMN2KDM4EFOXM1ALDH1A1CYP1A2
SCHEMBL21842123 0.90 SMN1; SMN2 (0.54) SMN1; SMN2KDM4EFOXM1ALDH1A1CYP1A2
SCHEMBL21842364 0.90 SMN1; SMN2 (0.54) SMN1; SMN2KDM4EFOXM1ALDH1A1CYP1A2
SCHEMBL2774793 0.88 KDM4E (0.53) SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6
SCHEMBL3530758 0.88 KDM4E (0.53) SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6
SCHEMBL6533951 0.88 KDM4E (0.53) SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6
SCHEMBL3536193 0.88 KDM4E (0.53) SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6
SCHEMBL5482641 0.86 KDM4E (0.55) SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6
SCHEMBL22759948 0.85 CYP1A2 (0.56) SMN1; SMN2KDM4EFOXM1ALDH1A1CYP1A2
SCHEMBL15395672 0.83 ALDH1A1 (0.42) SMN1; SMN2KDM4EFOXM1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10336743-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2019-07-02 US disclosed
US-20170247367-A1 AMINOPYRIMIDINE KINASE INHIBITORS P2K DYNAMICS INC. 2017-08-31 US disclosed
US-9629840-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2017-04-25 US disclosed
EP-2776432-B1 AMINOPYRIMIDINE KINASE INHIBITORS JASCO PHARMACEUTICALS LLC (US) 2017-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247367-A1 AMINOPYRIMIDINE KINASE INHIBITORS PIM1, PIM2, PIM3 SMN1; SMN2 3630/4885KDM4E 1116/4885FOXM1 1309/4885
US-10336743-B2 Aminopyrimidine kinase inhibitors PIM1, PIM2, PIM3 SMN1; SMN2 3482/4885KDM4E 1150/4885FOXM1 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.